COCH · Envoy Medical, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These matters raise substantial doubt about the Company's ability to continue as a going concern and although management has developed plans intended to support ongoing operations, such plans do not alleviate the substantial doubt.”View the 10-Q filed May 11, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $234K | $241K | $225K | $316K | $237K | — | |
| $961K | $874K | $742K | $789K | $498K | — | |
| -$727K | -$633K | -$517K | -$473K | -$261K | — | |
| — | -262.66% | -229.78% | -149.68% | -110.13% | — | |
| $13.38M | $12.49M | $10.18M | $8.96M | $4.98M | — | |
| $1.03M | $1.22M | $1.73M | $1.67M | $885K | — | |
| $7.99M | $7.93M | $6.83M | $7.26M | — | — | |
| — | — | — | $7.28M | $2.59M | — | |
| $23.36M | $22.51M | $19.48M | $18.68M | $8.94M | — | |
| -$23.12M | -$22.27M | -$19.26M | -$18.36M | -$8.71M | -$5.2M | |
| — | -9240.66% | -8558.22% | -5809.81% | -3673.42% | — | |
| — | $1.59M | $816K | — | — | — | |
| $9.42M | — | — | — | $6.13M | $37.67K | |
| $13K | -$1.49M | -$1.54M | -$11.56M | -$7.22M | — | |
| — | -$23.76M | -$20.8M | — | $20.74M | -$251.63K | |
| $2.36M | — | — | — | $1.5M | — | |
| -$23.11M | -$23.76M | -$20.8M | -$29.92M | -$15.92M | -$251.63K | |
| — | -9857.26% | -9242.22% | -9468.99% | -6718.57% | — | |
| -$28.13M | -$28.66M | -$27.97M | -$31.27M | -$15.92M | — | |
| -$23.11M | -$23.75M | -$20.8M | -$29.93M | -$15.93M | — | |
| USD/shares | — | -$1.23 | -$1.49 | -$2.54 | -$1.57 | — |
| USD/shares | — | -$1.23 | -$1.49 | -$2.54 | -$1.57 | — |
| shares | — | 23.26M | 18.79M | 12.3M | 10.12M | — |
| shares | — | 23.26M | 18.79M | 12.3M | 10.12M | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $4.27M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 79 similar-size Medical Devices companies (of 146 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| All Other Segments | $241,000 | $225,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| All Other Segments | -$22,270,000 | -$19,256,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 |
|---|---|---|
| All Other Segments | -9240.7% | -8558.2% |